NL8006869A - Radiologische bepalingsmethode in vivo. - Google Patents

Radiologische bepalingsmethode in vivo. Download PDF

Info

Publication number: NL8006869A
Authority: NL; Netherlands
Prior art keywords: radioactivity; indium; living; goat; oxinate
Prior art date: 1979-12-19

Application number

NL8006869A

Other languages

English (en)

Dutch (nl)

Original Assignee

Byk Mallinckrodt Cil Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-12-19

Filing date

1980-12-18

Publication date

1981-07-16

1980-12-18 Application filed by Byk Mallinckrodt Cil Bv filed Critical Byk Mallinckrodt Cil Bv

1981-07-16 Publication of NL8006869A publication Critical patent/NL8006869A/nl

Links

238000000034 method Methods 0.000 title claims description 30
206010000269 abscess Diseases 0.000 claims description 41
230000004054 inflammatory process Effects 0.000 claims description 16
229910052738 indium Inorganic materials 0.000 claims description 13
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 13
238000003384 imaging method Methods 0.000 claims description 11
230000002285 radioactive effect Effects 0.000 claims description 10
206010061218 Inflammation Diseases 0.000 claims description 8
230000001580 bacterial effect Effects 0.000 claims description 7
239000012503 blood component Substances 0.000 claims description 5
238000001514 detection method Methods 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
239000000941 radioactive substance Substances 0.000 claims description 2
INKYBOIVKCTYGX-UHFFFAOYSA-N indium;quinolin-8-ol Chemical compound [In].C1=CN=C2C(O)=CC=CC2=C1 INKYBOIVKCTYGX-UHFFFAOYSA-N 0.000 claims 3
241000283707 Capra Species 0.000 description 41
210000004027 cell Anatomy 0.000 description 25
210000003714 granulocyte Anatomy 0.000 description 24
210000004369 blood Anatomy 0.000 description 16
239000008280 blood Substances 0.000 description 16
230000035508 accumulation Effects 0.000 description 15
238000009825 accumulation Methods 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
239000000243 solution Substances 0.000 description 14
210000001519 tissue Anatomy 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
210000002381 plasma Anatomy 0.000 description 10
210000000056 organ Anatomy 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 8
239000013522 chelant Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000005725 8-Hydroxyquinoline Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
238000002372 labelling Methods 0.000 description 6
229960003540 oxyquinoline Drugs 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000013543 active substance Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
210000001015 abdomen Anatomy 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
210000003608 fece Anatomy 0.000 description 4
238000009472 formulation Methods 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
208000033809 Suppuration Diseases 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 3
229940055742 indium-111 Drugs 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000002751 lymph Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
150000004325 8-hydroxyquinolines Chemical class 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
210000004623 platelet-rich plasma Anatomy 0.000 description 2
239000012857 radioactive material Substances 0.000 description 2
239000012217 radiopharmaceutical Substances 0.000 description 2
229940121896 radiopharmaceutical Drugs 0.000 description 2
230000002799 radiopharmaceutical effect Effects 0.000 description 2
238000007560 sedimentation technique Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
206010004050 Bacterial pericarditis Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000000306 component Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
-1 for example Chemical group 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000005499 meniscus Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000012633 nuclear imaging Methods 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229950000550 sodium metrizoate Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/508—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for non-human patients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Optics & Photonics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Dispersion Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Apparatus For Radiation Diagnosis (AREA)
Nuclear Medicine (AREA)

NL8006869A 1979-12-19 1980-12-18 Radiologische bepalingsmethode in vivo. NL8006869A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/105,202 US4360509A (en)	1979-12-19	1979-12-19	Vivo radioassay process
US10520279		1979-12-19

Publications (1)

Publication Number	Publication Date
NL8006869A true NL8006869A (nl)	1981-07-16

Family

ID=22304590

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8006869A NL8006869A (nl)	1979-12-19	1980-12-18	Radiologische bepalingsmethode in vivo.

Country Status (7)

Country	Link
US (1)	US4360509A (fr)
JP (1)	JPS56100378A (fr)
BE (1)	BE886754A (fr)
CA (1)	CA1162330A (fr)
DE (1)	DE3048029A1 (fr)
GB (1)	GB2068728A (fr)
NL (1)	NL8006869A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0210684A1 (fr) *	1985-07-31	1987-02-04	MALLINCKRODT, INC.(a Missouri corporation)	Composition comprenant un composé métallique radioactif pour radiodiagnostic

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4574079A (en) *	1983-05-27	1986-03-04	Gavras Haralambos P	Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites
AU580958B2 (en) *	1983-07-07	1989-02-09	Mallinckrodt, Inc.	Sterile radioactive indium-containing aqueous solution
US4620971A (en) *	1983-12-22	1986-11-04	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Indium-bleomycin complex
US5792444A (en) *	1989-05-09	1998-08-11	The General Hospital Corporation	Labeled chemotactic peptides to image focal sites of infection or inflammation
US20080063599A1 (en) *	2002-11-18	2008-03-13	Jorge Setoain Quinquer	Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
DE102010023790A1 (de)	2010-06-15	2011-12-15	Heinrich-Heine-Universität Düsseldorf	Waschaktive Zusammensetzung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4017596A (en) *	1975-03-03	1977-04-12	Research Corporation	Radiopharmaceutical chelates and method of external imaging

1979
- 1979-12-19 US US06/105,202 patent/US4360509A/en not_active Expired - Lifetime
1980
- 1980-12-18 CA CA000367100A patent/CA1162330A/fr not_active Expired
- 1980-12-18 JP JP17966780A patent/JPS56100378A/ja active Pending
- 1980-12-18 BE BE0/203241A patent/BE886754A/fr not_active IP Right Cessation
- 1980-12-18 NL NL8006869A patent/NL8006869A/nl not_active Application Discontinuation
- 1980-12-18 GB GB8040610A patent/GB2068728A/en not_active Withdrawn
- 1980-12-19 DE DE19803048029 patent/DE3048029A1/de not_active Withdrawn

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0210684A1 (fr) *	1985-07-31	1987-02-04	MALLINCKRODT, INC.(a Missouri corporation)	Composition comprenant un composé métallique radioactif pour radiodiagnostic

Also Published As

Publication number	Publication date
CA1162330A (fr)	1984-02-14
JPS56100378A (en)	1981-08-12
US4360509A (en)	1982-11-23
GB2068728A (en)	1981-08-19
BE886754A (fr)	1981-04-16
DE3048029A1 (de)	1981-10-08

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1985-11-18	DNT	Communications of changes of names of applicants whose applications have been laid open to public inspection	Free format text: MALLINCKRODT DIAGNOSTICA (HOLLAND) B.V.
1988-02-01	BV	The patent application has lapsed

Publication	Publication Date	Title
KR100298682B1 (ko)	2001-11-22	시아닌염료-표시된세포의생체내세포추적용또는생체내세포의수명측정용용도
Thakur et al.	1976	Indium-111 labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions
Swisher et al.	1961	The blood grouping systems of dogs
Thakur et al.	1977	Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs
US4935223A (en)	1990-06-19	Labeled cells for use in imaging
Klonizakis et al.	1980	Radionuclide Distribution folowing Injection of 111Indium‐labelled Platelets
Riba et al.	1979	Imaging experimental infective endocarditis with indium-111-labeled blood cellular components.
GB1594187A (en)	1981-07-30	Diagnostic agents containing albumin and methods for making same
WO1999004827A1 (fr)	1999-02-04	Procede de detection de caillots de fibrine
Davis et al.	1968	Localization of 5‐hydroxytryptamine in blood platelets: an autoradiographic and ultrastructural study
Hindle et al.	1970	Pleural effusion and fibrosis during treatment with methysergide
CA1215372A (fr)	1986-12-16	Complexes chelateurs radioactifs renfermant des oxydes de n-pyridine
WO2018107205A1 (fr)	2018-06-21	Matériau radiomarqué pour administration ciblée
US4042677A (en)	1977-08-16	Technetium-99m labeled radiodiagnostic agents and method of preparation
Obrenovitch et al.	1984	Autoradiographic detections of 111indium-labeled platelets in brain tissue sections.
US4360509A (en)	1982-11-23	Vivo radioassay process
Stewart et al.	1955	The survival time of canine erythrocytes modified by influenza virus
US4348375A (en)	1982-09-07	Radioassay process and compositions useful therein
BERGMANN et al.	1982	Detection of cardiac transplant rejection with radiolabeled lymphocytes
Herion et al.	1964	Cr51-labeled endotoxin distribution in granulocytopenic animals
Kim et al.	2020	Rodent leukocyte isolation and radiolabeling for inflammation imaging study
Joist et al.	1983	Methodologic and basic aspects of indium-111 platelets
Goedemans et al.	1981	Radioassay process using an indium-8-hydroxyquinoline
LENTLE et al.	1976	Localization of acute inflammatory foci in man with 99mTc-sc labeled granulocytes
Kurantsin-Mills et al.	1989	Indium-111 oxine labeled erythrocytes: Cellular distribution and efflux kinetics of the label

NL8006869A - Radiologische bepalingsmethode in vivo. - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=22304590

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (6)

Family Cites Families (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events